Hemophilia Treatment Drugs Market : TOC


Back to Report

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Hemophilia Treatment Drugs Market

4. Market Overview
     4.1. Introduction
            4.1.1. Product Type Definition
            4.1.2. Industry Evolution / Developments
     4.2. Overview
     4.3. Market Dynamics
            4.3.1. Drivers
            4.3.2. Restraints
            4.3.3. Opportunities
     4.4. Global Hemophilia Treatment Drugs Market Analysis and Forecast, 2016–2026
            4.4.1. Market Revenue Projections (US$ Mn)
     4.5. Porter’s Five Force Analysis

5. Market Outlook
     5.1. Regulatory Scenario by Region/globally
     5.2. Key Mergers & Acquisitions 
     5.3. Pipeline Analysis
     5.4. Clinical Trial Analysis
     5.5. Technological Advancements

6. Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Product Type 
     6.1. Introduction & Definition
     6.2. Key Findings / Developments
     6.3. Global Hemophilia Treatment Drugs Market Value Forecast, by Product Type, 2016–2026
            6.3.1. Plasma derived coagulation factor concentrates 
                     6.3.1.1. Factor VIII
                     6.3.1.2. Factor IX
                     6.3.1.3. Others
            6.3.2. Recombinant coagulation factor concentrates 
                     6.3.2.1. Factor VIII
                     6.3.2.2. Factor IX
                     6.3.2.3. Others
            6.3.3. Others
     6.4. Global Hemophilia Treatment Drugs Market Attractiveness, by Product Type

7. Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Disease Indication 
     7.1. Introduction & Definition
     7.2. Key Findings / Developments
     7.3. Global Hemophilia Treatment Drugs Market Value Forecast by Disease Indication, 2016–2026
            7.3.1. Hemophilia A
            7.3.2. Hemophilia B
            7.3.3. Others
     7.4. Global Hemophilia Treatment Drugs Market Attractiveness, by Disease Indication

8. Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Distribution Channel 
     8.1. Introduction & Definition
     8.2. Key Findings / Developments
     8.3. Global Hemophilia Treatment Drugs Market Value Forecast, by Distribution Channel, 2016–2026
            8.3.1. Hospital Pharmacies 
            8.3.2. Retail Pharmacies 
            8.3.3. Online Pharmacies
     8.4. Global Hemophilia Treatment Drugs Market Attractiveness, by Distribution Channel

9. Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Region
     9.1. Key Findings
     9.2. Global Hemophilia Treatment Drugs Market Value Forecast, by Region
            9.2.1. North America 
            9.2.2. Europe 
            9.2.3. Asia Pacific 
            9.2.4. Latin America 
            9.2.5. Middle East & Africa 
     9.3. Global Hemophilia Treatment Drugs Market Attractiveness, by Country/Region

10. North America Hemophilia Treatment Drugs Market Analysis and Forecast
     10.1. Introduction
            10.1.1. Key Findings
     10.2. North America Hemophilia Treatment Drugs Market Value Forecast, by Product Type, 2016–2026
            10.2.1. Plasma derived coagulation factor concentrates 
                     10.2.1.1. Factor VIII
                     10.2.1.2. Factor IX
                     10.2.1.3. Others
            10.2.2. Recombinant coagulation factor concentrates 
                     10.2.2.1. Factor VIII
                     10.2.2.2. Factor IX
                     10.2.2.3. Others
            10.2.3. Others
     10.3. North America Hemophilia Treatment Drugs Market Value Forecast, by Disease Indication, 2016–2026
            10.3.1. Hemophilia A
            10.3.2. Hemophilia B
            10.3.3. Others
     10.4. North America Hemophilia Treatment Drugs Market Value Forecast, by Distribution Channel, 2016–2026
            10.4.1. Hospital Pharmacies 
            10.4.2. Retail Pharmacies 
            10.4.3. Online Pharmacies
     10.5. North America Hemophilia Treatment Drugs Market Value Forecast by Country, 2016–2026
            10.5.1. U.S.
            10.5.2. Canada
     10.6. North America Hemophilia Treatment Drugs Market Attractiveness Analysis 
                   10.6.1. By Product Type 
            10.6.2. By Disease Indication 
            10.6.3. By Distribution Channel 
            10.6.4. By Country

11. Europe Hemophilia Treatment Drugs Market Analysis and Forecast
     11.1.Introduction
     11.1.1. Key Findings
     11.2. Europe Hemophilia Treatment Drugs Market Value Forecast, by Product Type, 2016–2026
            11.2.1. Plasma derived coagulation factor concentrates 
                     11.2.1.1. Factor VIII
                     11.2.1.2. Factor IX
                     11.2.1.3. Others
            11.2.2. Recombinant coagulation factor concentrates 
                     11.2.2.1. Factor VIII
                     11.2.2.2. Factor IX
                     11.2.2.3. Others
            11.2.3. Others
     11.3. Europe Hemophilia Treatment Drugs Market Value Forecast, by Disease Indication, 2016–2026
            11.3.1. Hemophilia A
            11.3.2. Hemophilia B
            11.3.3. Others
     11.4. Europe Hemophilia Treatment Drugs Market Value Forecast, by Distribution Channel, 2016–2026
            11.4.1. Hospital Pharmacies 
            11.4.2. Retail Pharmacies 
            11.4.3. Online Pharmacies
     11.5. Europe Hemophilia Treatment Drugs Market Value Forecast, by Country/Sub-region, 2016–2026
            11.5.1. Germany
            11.5.2. U.K.
            11.5.3. France
            11.5.4. Spain
            11.5.5. Italy
            11.5.6. Rest of Europe
     11.6. Europe Hemophilia Treatment Drugs Market Attractiveness Analysis 
            11.6.1. By Product Type 
            11.6.2. By Disease Indication 
            11.6.3. By Distribution Channel 
            11.6.4. By Country/Sub-region

12. Asia Pacific Hemophilia Treatment Drugs Market Analysis and Forecast
     12.1.Introduction
            12.1.1. Key Findings
     12.2. Asia Pacific Hemophilia Treatment Drugs Market Value Forecast, by Product Type, 2016–2026
            12.2.1. Plasma derived coagulation factor concentrates 
                    12.2.1.1. Factor VIII
                     12.2.1.2. Factor IX
                     12.2.1.3. Others
            12.2.2. Recombinant coagulation factor concentrates 
                     12.2.2.1. Factor VIII
                     12.2.2.2. Factor IX
                     12.2.2.3. Others
            12.2.3. Others
     12.3. Asia Pacific Hemophilia Treatment Drugs Market Value Forecast, by Disease Indication, 2016–2026
            12.3.1. Hemophilia A
            12.3.2. Hemophilia B
            12.3.3. Others
     12.4. Asia Pacific Hemophilia Treatment Drugs Market Value Forecast, by Distribution Channel, 2016–2026
            12.4.1. Hospital Pharmacies 
            12.4.2. Retail Pharmacies 
            12.4.3. Online Pharmacies
     12.5. Asia Pacific Hemophilia Treatment Drugs Market Value Forecast, by Country/Sub-region, 2016–2026
            12.5.1. China
            12.5.2. Japan
            12.5.3. India
            12.5.4. Australia & New Zealand
            12.5.5. Rest of Asia Pacific
     12.6. Asia Pacific Hemophilia Treatment Drugs Market Attractiveness Analysis 
            12.6.1. By Product Type 
            12.6.2. By Disease Indication 
            12.6.3. By Distribution Channel 
            12.6.4. By Country/Sub-region

13. Latin America Hemophilia Treatment Drugs Market Analysis and Forecast
     13.1.Introduction
            13.1.1. Key Findings
     13.2. Latin America Hemophilia Treatment Drugs Market Value Forecast by Product Type, 2016–2026
            13.2.1. Plasma derived coagulation factor concentrates 
                     13.2.1.1. Factor VIII
                     13.2.1.2. Factor IX
                     13.2.1.3. Others
            13.2.2. Recombinant coagulation factor concentrates 
                     13.2.2.1. Factor VIII
                     13.2.2.2. Factor IX
                     13.2.2.3. Others
     13.3. Latin America Hemophilia Treatment Drugs Market Value Forecast, by Disease Indication, 2016–2026
            13.3.1. Hemophilia A
            13.3.2. Hemophilia B
            13.3.3. Others
     13.4. Latin America Hemophilia Treatment Drugs Market Value Forecast, by Distribution Channel, 2016–2026
            13.4.1. Hospital Pharmacies 
            13.4.2. Retail Pharmacies 
            13.4.3. Online Pharmacies
     13.5. Latin America Hemophilia Treatment Drugs Market Value Forecast, by Country/Sub-region, 2016–2026
            13.5.1. Brazil
            13.5.2. Mexico
            13.5.3. Rest of Latin America
     13.6. Latin America Hemophilia Treatment Drugs Market Attractiveness Analysis 
            13.6.1. By Product Type 
            13.6.2. By Disease Indication 
            13.6.3. By Distribution Channel 
            13.6.4. By Country

14. Middle East & Africa Hemophilia Treatment Drugs Market Analysis and Forecast
     14.1.Introduction
            14.1.1. Key Findings
     14.2. Middle East & Africa Hemophilia Treatment Drugs Market Value Forecast, by Product Type, 2016–2026
            14.2.1. Plasma derived coagulation factor concentrates 
                     14.2.1.1. Factor VIII
                     14.2.1.2. Factor IX
                     14.2.1.3. Others
            14.2.2. Recombinant coagulation factor concentrates 
                     14.2.2.1. Factor VIII
                     14.2.2.2. Factor IX
                     14.2.2.3. Others
            14.2.3. Others
     14.3. Middle East & Africa Hemophilia Treatment Drugs Market Value Forecast, by Disease Indication, 2016–2026
            14.3.1. Hemophilia A
            14.3.2. Hemophilia B
            14.3.3. Others
     14.4. Middle East & Africa Hemophilia Treatment Drugs Market Value Forecast, by Distribution Channel, 2016–2026
            14.4.1. Hospital Pharmacies 
            14.4.2. Retail Pharmacies 
            14.4.3. Online Pharmacies
     14.5. Middle East & Africa Hemophilia Treatment Drugs Market Value Forecast, by Country/Sub-region, 2016–2026
            14.5.1. GCC Countries
            14.5.2. South Africa
            14.5.3. Rest of Middle East & Africa
     14.6. Middle East & Africa Hemophilia Treatment Drugs Market Attractiveness Analysis 
            14.6.1. By Product Type 
            14.6.2. By Disease Indication 
            14.6.3. By Distribution Channel 
            14.6.4. By Country/Sub-region

15. Competition Landscape
     15.1.Market Player – Competition Matrix (by Tier and Size of companies)
     15.2.Market Share Analysis by Company (2017)
     15.3. Company Profiles
            15.3.1. Biotest AG.
                     15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.1.2. Business Overview
                     15.3.1.3. Product Portfolio 
                     15.3.1.4. Financial Overview 
                     15.3.1.5. SWOT Analysis 
                     15.3.1.6. Strategic overview
            15.3.2. Bayer AG
                     15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.2.2. Business Overview
                     15.3.2.3. Product Portfolio 
                     15.3.2.4. Financial Overview 
                     15.3.2.5. SWOT Analysis 
            15.3.3. CSL Limited
                     15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.3.2. Business Overview
                     15.3.3.3. Product Portfolio 
                     15.3.3.4. Financial Overview 
                     15.3.3.5. SWOT Analysis 
                     15.3.3.6. Strategic overview
            15.3.4. F. Hoffmann-La Roche Ltd.
                     15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.4.2. Business Overview
                     15.3.4.3. Product Portfolio 
                     15.3.4.4. Financial Overview 
                     15.3.4.5. SWOT Analysis 
                     15.3.4.6. Strategic overview 
            15.3.5. Kedrion
                     15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.5.2. Business Overview
                     15.3.5.3. Product Portfolio 
                     15.3.5.4. Financial Overview 
                     15.3.5.5. SWOT Analysis 
                     15.3.5.6. Strategic overview
            15.3.6. Novo Nordisk A/S
                                     15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.6.2. Business Overview
                     15.3.6.3. Product Portfolio 
                     15.3.6.4. Financial Overview 
                     15.3.6.5. SWOT Analysis 
                     15.3.6.6. Strategic overview
            15.3.7. Octapharma
                     15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.7.2. Business Overview
                     15.3.7.3. Product Portfolio 
                     15.3.7.4. Financial Overview 
                     15.3.7.5. SWOT Analysis 
                     15.3.7.6. Strategic overview
            15.3.8. Pfizer, Inc
                     15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.8.2. Business Overview
                     15.3.8.3. Product Portfolio 
                     15.3.8.4. Financial Overview 
                     15.3.8.5. SWOT Analysis 
                     15.3.8.6. Strategic overview 
            15.3.9. Sanofi
                     15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.9.2. Business Overview
                     15.3.9.3. Product Portfolio 
                     15.3.9.4. Financial Overview 
                     15.3.9.5. SWOT Analysis 
                     15.3.9.6. Strategic overview
           15.3.10. Shire Plc.
                     15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.10.2. Business Overview
                     15.3.10.3. Product Portfolio 
                     15.3.10.4. Financial Overview 
                     15.3.10.5. SWOT Analysis 
                     15.3.10.6. Strategic overview

List of Tables

Table 01 Global Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
Table 02 Global Hemophilia Treatment Drugs Market Value (US$ Mn) Forecast, by Recombinant Coagulation Factor Concentrates, 2016–2026
Table 03 Global Hemophilia Treatment Drugs Market Value (US$ Mn) Forecast, by Plasma derived coagulation factor concentrates, 2016–2026
Table 04 Global Hemophilia Treatment Drugs Market Value (US$ Mn) Forecast, by Disease Indication, 2016–2026
Table 05 Global Hemophilia Treatment Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 06 North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Country, 2016–2026
Table 07 North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
Table 08 North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Disease Indication, 2016–2026
Table 09 North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 10 Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 11 Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
Table 12 Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Disease Indication, 2016–2026
Table 13 Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 14 Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 15 Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
Table 16 Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Disease Indication, 2016–2026
Table 17 Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 18 Latin America  Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 19 Latin America  Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
Table 20 Latin America  Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Disease Indication, 2016–2026
Table 21 Latin America  Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 22 Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 23 Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
Table 24 Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Disease Indication, 2016–2026
Table 25 Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026

List of Figures

Figure 01 Global Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others)Market Size, by Product Type  (US$ Mn), 2017
Figure 02 Global Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others)Market Share Analysis by Region, 2017
Figure 03 Global Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others)Market Opportunity Map, by Product Type
Figure 04 Global Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others)Market Opportunity Map, by Disease Indication
Figure 05 Global Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others)Market Opportunity Map, by Distribution Channel 
Figure 06 Global Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Product Type, 2017 and 2026
Figure 07 Global Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Product Type, 2018–2026
Figure 08 Global Hemophilia Treatment Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Recombinant coagulation factor concentrates, 2016–2026
Figure 09 Global Hemophilia Treatment Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Plasma-derived coagulation factor concentrates, 2016–2026
Figure 10 Global Hemophilia Treatment Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2016–2026
Figure 11 Global Bispecific & Next Generation Recombinant Products Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
Figure 12 Global Gene Therapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
Figure 13 Global Hemophilia Treatment Drugs Market Value Share, by Distribution Channel, 2017 and 2026
Figure 14 Global Hemophilia Treatment Drugs Market Value Share, by Disease Indication, 2017 and 2026
Figure 15 Global Hemophilia Treatment Drugs Market Attractiveness, by Disease Indication, 2018–2026
Figure 16 Global Hemophilia Treatment Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Hemophilia A, 2016–2026
Figure 17 Global Hemophilia Treatment Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Hemophilia B, 2016–2026
Figure 18 Global Hemophilia Treatment Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2016–2026
Figure 19 Global Hemophilia Treatment Drugs Market Value Share, by Distribution Channel, 2017 and 2026
Figure 20 Global Hemophilia Treatment Drugs Market Attractiveness, by Distribution Channel, 2018–2026
Figure 21 Global Hemophilia Treatment Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2016–2026
Figure 22 Global Hemophilia Treatment Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2016–2026
Figure 23 Global Hemophilia Treatment Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacies, 2016–2026
Figure 24 North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
Figure 25 North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Country, 2017 and 2026
Figure 26 North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Country, 2018–2026
Figure 27 North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Product Type, 2017 and 2026
Figure 28 North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Product Type, 2018–2026
Figure 29 North America Bispecific & Next Generation Recombinant Factor Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
Figure 30 North America Gene Therapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
Figure 31 North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Disease Indication, 2017 and 2026
Figure 32 North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Disease Indications, 2018–2026
Figure 33 North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Distribution Channel, 2017 and 2026
Figure 34 North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Distribution Channel, 2018–2026
Figure 35 Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
Figure 36 Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Country/Sub-region, 2017 and 2026
Figure 37 Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 38 Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Product Type, 2017 and 2026
Figure 39 Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Product Type, 2018–2026
Figure 40 Europe Bispecific & Next Generation Recombinant Factor Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
Figure 41 Europe Gene Therapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
Figure 42 Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Disease Indication, 2017 and 2026
Figure 43 Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Disease Indications, 2018–2026
Figure 44 Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Distribution Channel, 2017 and 2026
Figure 45 Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Distribution Channel, 2018–2026
Figure 46 Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
Figure 47 Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Country/Sub-region, 2017 and 2026
Figure 48 Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 49 Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Product Type, 2017 and 2026
Figure 50 Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Product Type, 2018–2026
Figure 51 Asia Pacific Bispecific & Next Generation Recombinant Factor Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
Figure 52 Asia Pacific Gene Therapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
Figure 53 Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Disease Indication, 2017 and 2026
Figure 54 Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Disease Indications, 2018–2026
Figure 55 Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Distribution Channel, 2017 and 2026
Figure 56 Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Distribution Channel, 2018–2026
Figure 57 Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
Figure 58 Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Country/Sub-region, 2017 and 2026
Figure 59 Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 60 Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Product Type, 2017 and 2026
Figure 61 Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Product Type, 2018–2026
Figure 62 Latin America Bispecific & Next Generation Recombinant Factor Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
Figure 63 Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Disease Indication, 2017 and 2026
Figure 64 Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Disease Indications, 2018–2026
Figure 65 Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Distribution Channel, 2017 and 2026
Figure 66 Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Distribution Channel, 2018–2026
Figure 67 Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
Figure 68 Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Country/Sub-region, 2017 and 2026
Figure 69 Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 70 Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Product Type, 2017 and 2026
Figure 71 Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Product Type, 2018–2026
Figure 72 Middle East & Africa Bispecific & Next Generation Recombinant Factor Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
Figure 73 Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Disease Indication, 2017 and 2026
Figure 74 Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Disease Indications, 2018–2026
Figure 75 Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Distribution Channel, 2017 and 2026
Figure 76 Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Distribution Channel, 2018–2026

Request Methodology of This Report

Request Methodology

First Time Buyer ?

Check Discount

Request a Sample

Click button below to request a sample of this report

Request Sample

About This Report


  • Rep Id : XPLREP2784
  • Publised On : December, 2018
  • No. of Pages : 188
  • Category : Pharmaceutical
  • Publisher : Transparency Market Research